Abdelmassih Youssef, El-Khoury Sylvain, Chelala Elias, Slim Elise, Cherfan Carole G, Jarade Elias
J Refract Surg. 2017 Sep 1;33(9):610-616. doi: 10.3928/1081597X-20170621-02.
To evaluate 6-month and 2-year safety and clinical outcomes of Visian toric Implantable Collamer Lens (toric ICL) (STAAR Surgical, Monrovia, CA) implantation for the treatment of residual refractive errors after sequential intracorneal ring segments (ICRS) insertion and cross-linking (CXL) in keratoconus.
This consecutive case series included the results of a three-step ICRS-CXL-toric ICL procedure in 16 eyes of 13 patients with moderate to severe keratoconus (stages II and III of Amsler-Krumeich classification). The ICRS and CXL procedures were performed sequentially with an interval of 4 weeks and the toric ICL implantation was performed at least 6 months after CXL. Data were collected preoperatively, at 6 months after sequential ICRS-CXL, and at 6 and 24 months following toric ICL implantation. All 16 eyes were evaluated at the 2-year follow-up.
There was a significant decrease in keratometry (steep, flat, and maximum) and refraction (sphere and spherical equivalence, but not cylinder) and a significant increase in both uncorrected (UDVA) (from 1.06 to 0.76 logMAR, P = .004) and corrected (CDVA) (from 0.42 to 0.26 logMAR; P = .002) distance visual acuity 6 months following sequential ICRS-CXL, whereas UDVA and refraction significantly improved 6 months after ICL insertion (UDVA reached 0.33 logMAR, P = .001). At the 24-month follow-up, UDVA and keratometric readings were stable, whereas CDVA, sphere, and cylinder showed a significant improvement.
Implantation of Visian toric ICL following sequential ICRS insertion and CXL is an effective and safe option for correcting high residual refractive error and improving visual acuity in patients with moderate to severe keratoconus in the long term. [J Refract Surg. 2017;33(9):610-616.].
评估Visian toric可植入式角膜胶原晶状体(toric ICL)(STAAR Surgical,蒙罗维亚,加利福尼亚州)植入术治疗圆锥角膜患者在序贯植入角膜内环片(ICRS)和交联(CXL)后残余屈光不正的6个月和2年安全性及临床效果。
该连续病例系列纳入了13例中重度圆锥角膜患者(Amsler-Krumeich分类的II期和III期)的16只眼,采用三步ICRS-CXL-toric ICL手术。ICRS和CXL手术序贯进行,间隔4周,toric ICL植入在CXL后至少6个月进行。术前、序贯ICRS-CXL后6个月、toric ICL植入后6个月和24个月收集数据。所有16只眼均在2年随访时进行评估。
序贯ICRS-CXL后6个月,角膜曲率(陡峭、平坦和最大值)和屈光不正(球镜和球镜等效度,但柱镜无变化)显著降低,未矫正远视力(UDVA)(从1.06 logMAR提高到0.76 logMAR,P = 0.004)和矫正远视力(CDVA)(从0.42 logMAR提高到0.26 logMAR;P = 0.002)均显著提高,而ICL植入后6个月UDVA和屈光不正显著改善(UDVA达到0.33 logMAR,P = 0.001)。在24个月随访时,UDVA和角膜曲率读数稳定,而CDVA、球镜和柱镜显示显著改善。
对于中重度圆锥角膜患者,序贯植入ICRS和CXL后植入Visian toric ICL是长期矫正高度残余屈光不正和提高视力的有效且安全的选择。[《屈光手术杂志》。2017;33(9):610 - 616。]